HOME > Newsletter > FDA Warns of Bladder Cancer Risk with Actos :: Manufacturer of Eleotin – Eastwoodcompanies.com

NEWSLETTER

Reg. Date : 2011.07.14 12:40
FDA Warns of Bladder Cancer Risk with Actos
Views : 4151 

 


FDA Warns of Bladder Cancer Risk with Actos

Patients taking the diabetes drug Actos (pioglitazone) for more than a year may have an increased risk of bladder cancer, according to the FDA. The warning came few days after German and France banned the use of the drug, citing similar concerns.

In a study involving more than 193,000 diabetics, compared to never being exposed to pioglitazone, the pioglitazone therapy for longer than 12 months was associated with a 40 percent increase in risk for bladder cancer, the FDA said. The five-year data of an ongoing ten-year study show that patients with the longest exposure to and the highest cumulative dose of the drug were at greater risk.

The new cancer warning will be required to appear on the labeling. The FDA is advising doctors not to use Actos in patients with bladder cancer and said diabetes patients should tell their doctor if they are having symptoms of bladder cancer such as blood or red color in urine, an urgent need to urinate or pain while urinating and pain in back or lower abdomen.

Actos is now the second medication in a class of drugs called thiazolidinedione (TZD) to be associated with serious side effects within the past year. Last year, the use of Avandia (rosiglitazone) was severely restricted in several countries including the U.S. because of an increased risk of heart attacks.

Actos is used to control blood sugar and is sold alone or in combination with metformin and glimepiride. Actos, Takeda Pharmaceuticals’ best-selling drug approved in 1999, was prescribed to more than 2 million patients with sales of $3.4 billion in 2010.

Since information about the potential bladder cancer risk associated with Actos first surfaced last year, a number of former users diagnosed with bladder cancer are considering pursuing an Actos lawsuit against Takeda Pharmaceuticals for failing to fully research the side effects of the medication or adequately warn about the potential risk of bladder cancer.


Eleotin® is the only known 100% natural normalizer of long term chronic metabolic disorders such as diabetes. Eleotin® has been approved in many countries.


For more information, visit
www.eastwoodcompanies.com / www.medireport.com
Or email us at info@eastwoodcos.com
Affiliate Program for Eleotin Family
"Recession Free High Income Job. Work At Home. 100% Flexibility in Work Schedule.
Easy. No Training Necessary. No Risk.

 


Total 70
No. SUBJECT DATE VIEW
78 Medireport - Alzehimer Disease: Type 3 Diabetes  01-21 1643
77 Medireport - MAO, Kalimera, Santorini, AQ Omega, Pango  01-13 1091
76 Medireport - Male Problems  09-02 1697
75 Fancy a cuppa?  07-21 1705
74 Childhood Obesity  04-30 2004
73 Brain Drain - The effects of Diabetes on Dementia.  04-01 2173
72 How to get an A+? B’ Brain-conscious.  10-11 2347
71 Cholesterol & You   10-11 2388
70 A great opportunity for FB users!  06-11 3958
69 “Eastwood” on Social Network! (Complimentary Gift!)  06-11 3873
67 Recent Developments of Eastwood Bio-Medical Research Canada Inc.  03-26 4060
66 30+ reasons; why we are different from Other Blood Sugar Control Products?  03-15 4157
65 Male Sexual Performance Enhancement  01-26 6638
64 Secretive Health Formula For Chinese Leaders  01-23 3740
63 Three Essential Nutrients for Metabolism Disorders  01-23 3387
62 Join the Conversation and Make Money  01-16 2399
61 Poor Sleep Quality Increases Hypertension Risk  10-28 3163
60 Medical Blunder (4) Power Shift and Medicine  10-28 3010
59 Medical Bluders (3): Science is all good?   10-21 2824
58 Medical Blunders (2): Lack of Intuition  10-13 3779
57 Medical Bluders and Miracles (1) Nurses.   10-08 3803
56 Eating Nuts Improves Diabetes Control  08-23 4990
55 Building Muscle Can Reduce Diabetes Risk  08-10 4577
54 Any Eleotin experience to share?  08-10 3835
53 FDA Warns of Bladder Cancer Risk with Actos  07-14 4151
 
 
 1  2  3  
    Eastwood Bio-Medical Research Inc. Unit 1130-4871 Shell Road Richmond, B.C. Canada, V6X 3Z6
Tel: 604.247.2100 or 1.888.669.4372      Email: info@eastwoodcos.com
Copyright© 2011 Eastwood Companies